🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Fostering Data Sharing

Search Papers Authors Institutions Grants FAIR About

TheSindex

Fostering Data Sharing

Empowering the data sharing that empowers science — an open, citation-grounded index for datasets.

Product

Search
API
Explore
Rankings

Resources

Methodology
Data Sources
Documentation
Press

Organization

About
Team
Wikidata

© 2026 theSindex. All rights reserved.

Home
Papers
Predictors of HIV rebound differ by timing of antiretroviral therapy initiation

Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Predictors of HIV rebound differ by timing of antiretroviral therapy initiation

JCI Insight(2024)10.1172/jci.insight.173864Source: DataRank Database

Predictors of HIV rebound differ by timing of antiretroviral therapy initiation is a research paper published in JCI Insight (2024). On theSindex it has a DataRank of 0.720. It has been cited 27 times, with 18 citing works in its 1-hop citation network.

N/A

0.720DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access27 citations · 18 citing works in its network

Cite:

Linked data & code

nct doi

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT03001128

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (22 grants)Impact (FWCI 7.81)OA: goldTopics (50)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

FFindable (1/2)

Has DOI

AAccessible (1/2)

Open Access

IInteroperable (0/2)

RReusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 69%Citation Network 31%

Base Score Contribution

0.500

From this paper's citation signal

Citation Network Contribution

0.220

From 10 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 18 citers.

Assessing advances in three decades of clinical antiretroviral therapy on the HIV-1 reservoir
Journal of Clinical Investigation20248 citations33 referencesContributes 0.067
Post-intervention control in HIV immunotherapy trials
Current Opinion in HIV and AIDS202412 citations67 referencesContributes 0.038
Contribution of intact viral genomes persisting in blood and tissues during ART to plasma viral rebound in SHIV-infected rhesus macaques
iScience20257 citations62 referencesContributes 0.034
HIV-1 reservoir landscape of post-treatment control
Current Opinion in HIV and AIDS20244 citations48 referencesContributes 0.034
Cellular Tropism and Viral Genetics in Appendix Tissue Reservoirs of Subtype C HIV-1–Infected Aviremic Persons
The Journal of Infectious Diseases20251 citations36 referencesContributes 0.019

Authors (26)

Meghan Melberg,Autumn Kittilson,Mohamed Abdel‐Mohsen ORCID,Yijia Li ORCID,Evgenia Aga

Live enrichment

PubMed:38329130 PMC:PMC10967395 OpenAlex:https://openalex.org/W4394729437

National Institute of Allergy and Infectious Diseases

Grant: 068636

National Institute of Allergy and Infectious Diseases

Grant: 068634

National Institute of Allergy and Infectious Diseases

Grant: 106701

National Institute of Allergy and Infectious Diseases

Grant: 036214

National Institute of Allergy and Infectious Diseases

Grant: 131385

Merck

Grant: n/a

NIAID NIH HHS

Grant: R24 AI143502

NIAID NIH HHS

Grant: UM1 AI069481

NIAID NIH HHS

Grant: U01 AI068634

NIAID NIH HHS

Grant: P01 AI131385

NIAID NIH HHS

Grant: P30 AI036214

NIAID NIH HHS

Grant: UM1 AI106701

NIAID NIH HHS

Grant: T32 AI007387

NIAID NIH HHS

Grant: UM1 AI068634

NIAID NIH HHS

Grant: UM1 AI068636

NIAID NIH HHS

Grant: UM1 AI069494

NIAID NIH HHS

Grant: HHSN272201500017C

NIAID NIH HHS

Grant: U24 AI143502

NIAID NIH HHS

Grant: UM1 AI069432

NIAID NIH HHS

Grant: P30 AI050410

National Institutes of Health

Grant: 3UM1AI068636-19SC

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

National Institutes of Health

Grant: 5U01AI068634-03

Statistical and Data Management Center for the AIDS Clinical Trials Group

FWCI

7.81

Citation Percentile

1.0%

Influential Citations

2

Citation Trend

2024

2025

2026

goldLicense: cc-by

journalhttp://insight.jci.org/articles/view/173864/files/pdf

GOLDhttp://insight.jci.org/articles/view/173864/files/pdf

publisherhttp://insight.jci.org/articles/view/173864/files/pdf

publisherhttps://insight.jci.org/articles/view/173864/files/pdf

journalhttps://doi.org/10.1172/jci.insight.173864

Fields of Study

HIV/AIDS Research and InterventionsHIV Research and TreatmentHIV/AIDS drug development and treatmentMedicine0301 basic medicine03 medical and health sciencesHumansHIV InfectionsProvirusesCD8-Positive T-LymphocytesViral LoadDNA

MeSH Terms

DNAHumansProvirusesHIV InfectionsCD8-Positive T-LymphocytesViral Load

Keywords

Antiretroviral therapyHuman immunodeficiency virus (HIV)MedicinePsychological interventionViral loadInternal medicineIntensive care medicineVirologyPsychiatryadaptive immunityAids/hivAids VaccineBiomedical and clinical sciencesImmunologyClinical Trials and Supportive ActivitiesAIDS Clinical Trials Group A5345 Study Team610HIV InfectionsCD8-Positive T-LymphocytesProvirusesClinical Research616HumansHealth sciencesDNAInfectious DiseasesGood Health and Well BeingMedical MicrobiologyHIV/AIDSSexually Transmitted InfectionsClinical MedicineInfection

Sustainable Development Goals

SDG 0: Good health and well-being

Related Papers (10)

Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial

N/A

1.6DataRank · unranked

Nature Medicine(2023)

co-cited

10.1038/s41591-023-02547-6

Autologous neutralizing antibody responses after antiretroviral therapy in acute and early HIV-1

N/A

0.383DataRank · unranked

Journal of Clinical Investigation(2024)

co-cited

10.1172/jci176673

Interventions during Early Infection: Opening a Window for an HIV Cure?

N/A

0.428DataRank · unranked

Viruses(2024)

co-cited

10.3390/v16101588

Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial

N/A

2.7DataRank · unranked

Nature Medicine(2022)

co-cited

10.1038/s41591-022-02023-7

The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies

N/A

7.0DataRank · unranked

Cell Host & Microbe(2020)

co-cited

10.1016/j.chom.2020.03.014

Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV

N/A

1.5DataRank · unranked

Nature Communications(2021)

co-cited

10.1038/s41467-021-24077-w

CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication

N/A

2.6DataRank · unranked

Journal of Clinical Investigation(2021)

co-cited

10.1172/jci144486

Integration features of intact latent HIV-1 in CD4+ T cell clones contribute to viral persistence

The Journal of Experimental Medicine(2021)

co-cited

10.1084/jem.20211427

Long-term effects of early antiretroviral initiation on HIV reservoir markers: a longitudinal analysis of the MERLIN clinical study

The Lancet Microbe(2021)

co-cited

10.1016/s2666-5247(21)00010-0

A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies

The Journal of Experimental Medicine(2021)

co-cited

10.1084/jem.20201908